How Much Do Cancer Drugs Cost?

The line from the pharmaceutical manufacturers have always been that it costs billions to develop new drugs. And they have to recoup their costs for the drugs that don't make it. This is why we have cancer treatments that cost well over $100,000 each year.But now the truth is out.Tufts Center for the Study of Drug Development conducted a study ondevelopment costs of cancer drugs.What they found is a much lower total for development of a cancer drug." A new analysis finds the magic number is $648 million, which is substantially less than an earlier albeit controversial estimate of $2.6 billion for the cost to develop any and all new medicines, in general. As with that earlier estimate by the Tufts Center for the Study of Drug Development, though, this latest analysis is already engendering criticism, a reflection of an ongoing debate over true development costs and how these should be calculated. This is important because the pharmaceutical industry has often used R&D costs to justify its pricing. "“These results suggest that pharmaceutical drug development is extremely lucrative and the current drug prices are not necessarily justified by the R&D spending on these drugs, ’’ the researchers who conducted the new analysis — Dr. Vinay Prasad of Oregon Health and Science University and Dr. Sham Mailankody of Memorial Sloan Kettering Cancer Center — wrote in JAMA Internal Medicine. To arrive at their $648 million estimate, the rese...
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: cancer costs medical research medication costs Source Type: blogs

Related Links:

PMID: 31985642 [PubMed - in process]
Source: Hand Surgery - Category: Surgery Authors: Tags: Plast Reconstr Surg Source Type: research
CONCLUSIONS: Based on the available evidence, there is no increased risk of complications for elective hand surgery in patients with prior breast cancer treatment. Breast cancer patients with preexisting ipsilateral lymphedema carry slightly increased risk of postoperative infection and worsening lymphedema. It is the authors' opinion and recommendation that elective hand surgery with a tourniquet is not a contradiction in patients who have received previous breast cancer treatments. PMID: 31985641 [PubMed - in process]
Source: Hand Surgery - Category: Surgery Authors: Tags: Plast Reconstr Surg Source Type: research
Publication date: 2020Source: European Journal of Radiology Open, Volume 7Author(s): Ryusuke Murakami, Nachiko Uchiyama, Hitomi Tani, Tamiko Yoshida, Shinichiro KumitaAbstractPurposeTo compare observer performance between synthetic mammography (2DSM) and full-field digital mammography (FFDM) for breast cancer detection and visibility.MethodA retrospective analysis was conducted on 136 histopathologically proven cases of breast cancer in patients who underwent FFDM and digital breast tomosynthesis (DBT). 2DSM images were reconstructed from DBT data, and 2DSM and FFDM images were reviewed and evaluated for mammographic featu...
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
Publication date: Available online 28 January 2020Source: Journal of Biomedical InformaticsAuthor(s): Akhilesh Kumar Bajpai, Sravanthi Davuluri, Kriti Tiwary, Sithalechumi Narayanan, Sailaja Oguru, Kavyashree Basavaraju, Deena Dayalan, Kavitha Thirumurugan, Kshitish K. AcharyaAbstractIn absence of periodic systematic comparisons, biologists/bioinformaticians may be forced to make a subjective selection among the many protein-protein interaction (PPI) databases and tools. We conducted a comprehensive compilation and comparison of such resources. We compiled 375 PPI resources, short-listed 125 important ones (both lists are ...
Source: Journal of Biomedical Informatics - Category: Information Technology Source Type: research
Publication date: Available online 27 January 2020Source: International Journal of PharmaceuticsAuthor(s): Yiliang Yang, Yang Long, Yashi Wang, Kebai Ren, Man Li, Zhirong Zhang, Bing Xiang, Qin HeAbstractTumor growth and metastasis are multistep processes regulated by multiple signaling pathways. The successful treatment of cancer largely depends on the ability to inhibit metastatic process. Multiphase inhibition of metastasis is a promising approach. Here, we described a targeting delivery system which was constructed by mixing hyaluronic acid-D-α-tocopheryl succinate (HA-TOS, HT) and low molecular weight heparin-TO...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conditions:   Breast Cancer;   Invasive Breast Cancer;   in Situ Breast Cancer;   Genetic Testing Interventions:   Behavioral: Standard Genetic Counseling;   Behavioral: Quantitative Genetic Counseling Sponsors:   Dana-Farber Cancer Institute;   Myriad Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   DCIS;   Invasive Breast Cancer Interventions:   Other: Stool sample;   Other: Skin Swab Sample Sponsor:   Case Comprehensive Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Invasive Breast Cancer Interventions:   Drug: Cemiplimab;   Drug: Paclitaxel;   Drug: Carboplatin (not mandatory);   Drug: Doxorubicin;   Drug: Cyclophosphamide Sponsor:   Medical College of Wisconsin Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Is the combination of oral metronomic vinorelbine plus letrozole safe and effective for ER+ breast cancer?Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Publication date: March 2020Source: Colloid and Interface Science Communications, Volume 35Author(s): Nidhi Jain Singhai, Rahul Maheshwari, Suman RamtekeAbstractTriple-negative breast cancer requires high treatment specificity and efficacy due to its aggressive nature. In the present investigation, multi-walled carbon-nanotubes (MWCNTs) were functionalized using Hyaluronic acid (HA) and α-Tocopheryl succinate (α-TOS) and loaded with Doxorubicin (Dox) to obtained novel α-TOS-HA-MWCNTs/Dox conjugate to achieve enhanced cellular-placement and anticancer-therapeutic action against CD44 receptors overexpressin...
Source: Colloids and Interface Science Communications - Category: Nanotechnology Source Type: research
More News: Blogging | Breast Cancer | Cancer | Cancer & Oncology | Internal Medicine | Research | Science | Study